Clinical Trials Logo
  1. Home
  2. Reflux Esophagitis
  3. NCT04531475

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Reflux Esophagitis Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Double-simulation, Active Comparator-controlled, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of X842 Capsules at Different Dosages in Patients With Reflux Esophagitis

Clinical Trial Summary

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

Clinical Trial Description

It is designed as a multicenter, randomized, double-blind, double-simulation, high and low dose group, active comparator-controlled, parallel-group study to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04531475
Study type Interventional
Source Jiangsu Sinorda Biomedicine Co., Ltd
Contact Ming Lu
Phone +8618684676235
Email lum@sinorda.com
Status Recruiting
Phase Phase 2
Start date January 22, 2019
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06170060 - Treatment of Reflux With Sleeve Gastrectomy N/A
Not yet recruiting NCT06062225 - Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Not yet recruiting NCT06056973 - Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis Phase 4
Completed NCT01008696 - An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Phase 4
Recruiting NCT05899491 - Role of ARMA in Selective Subset of Refractory GERD Patients. N/A
Recruiting NCT01311908 - Incidence of Reflux Esophagitis After Pancreaticoduodenectomy N/A
Completed NCT03214081 - Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Not yet recruiting NCT01560598 - Adipokines and the Risk of Reflux Esophagitis N/A
Completed NCT00859287 - Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis N/A
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Recruiting NCT04657848 - Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy N/A
Completed NCT02477475 - Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes N/A
Completed NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Completed NCT01381991 - The Efficacy of i-Scan for Detecting Reflux Esophagitis N/A
Completed NCT04673643 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis N/A
Completed NCT00586963 - Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis N/A
Completed NCT00634114 - Reflux Esophagitis Phase III Study (Maintenance Treatment) Phase 3
Completed NCT03388047 - Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus N/A
Recruiting NCT00155805 - Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus N/A